Business
Notice of Results and Change in reporting currency
Notice of Results and Change in reporting currency.
About this update from Shield Therapeutics Plc
[{"type":"text","content":"\n\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\n \nNotice of interim results\nChange in reporting currency\n \nLondon, UK, 6 September 2023: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company focused on the commercialisation of its innovative oral iron therapy for iron deficiency, Accrufer®/Feraccru® (ferric maltol), will announce its interim results for the six months ended 30 June 2023 on Thursday 28 September 2023.\n \nInvestor presentation\nCEO, Greg Madison, and CFO, Hans-Peter Rudolf, will be hosting a live online presentation relating to the interim results via the Investor Meet Company platform at 16.30 (BST) on Thursday 28 September 2023.\n \nThe presentation is open to all existing and potential investors. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 09:00 (BST) the day before the meeting or at any time during the live presentation.\nInvestors can sign up to Investor Meet Company for free and add to meet Shield Therapeutics plc via:\n \nhttps://www.investormeetcompany.com/shield-therapeutics-plc/register-investor\n \nInvestors who already follow Shield Therapeutics plc on the Investor Meet Company platform will automatically be invited.\n \nChange in reporting currency\nReflecting the increasing importance of the Group's U.S. operations on its financial results, Shield is also announcing that it will change its reporting currency from Pounds Sterling to US Dollars (USD) effective 1 January 2023.The interim results for the six months ending 30 June 2023 will include condensed, consolidated USD financial information for H123 and FY22. In accordance with the relevant accounting standards, comparative historic financial information for FY 2022 will be published in USD alongside the full FY 2023 results in the first half of 2024.\n \nFor further information please contact:\n \n\n\n\nShield Therapeutics plc\n\n\nwww.shieldtherapeutics.com\n\n\n\n\nGreg Madison, CEO\n\n\n+44 (0) 191 511 8500\n\n\n\n\nHans-Peter Rudolf, CFO\n\n\n\n\n\n\n\n \nNominated Adviser and Joint Broker\n\n\n\n\n\n\n\nPeel Hunt LLP\n\n\n\n\n\n\n\nJames Steel/Patrick Birkholm\n\n\n+44 (0)20 7418 8900\n\n\n\n\n \nJoint Broker\nfinnCap Ltd \nGeoff...